Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 Injection in Non-diabetic Obese Adults
CTR20231528Phase 2Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- May 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HRS9531 in Overweight, obesity, sponsored by Fujian Shengdi Pharmaceuticals. Started May 2023; status: completed.
02
Drugs
HRS9531
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on CTR20231528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231528.